GlycoMimetics (GLYC)
(Delayed Data from NSDQ)
$1.83 USD
+0.11 (6.40%)
Updated May 3, 2024 04:00 PM ET
After-Market: $1.84 +0.01 (0.55%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Brokerage Reports
0 items in cart
GlycoMimetics, Inc. [GLYC]
Reports for Purchase
Showing records 81 - 100 ( 157 total )
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Rivipansel Phase 3 Presentation and GMI-1687 Preclinical Data Oral Presentation at ASCAT
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Venetoclax + Uproleselan Could Be a Good Match for AML
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
2Q20 Results; Uproleselan Phase 3 Back on Track
Provider: H.C. Wainwright & Co., Inc.
Analyst: WHITE E
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Late-Stage Programs, Uproleselan and Rivipansel, Support Higher Valuation
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Reiterating Buy Following Our Recent Meeting With Management
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Reminder to Register for Our Call with GLYC''s Mgmt. Team TODAY at 10AM ET
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Reminder to Register for Our Call with LYC''s Mgt. Team Wednesday 10AM ET
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Perfect Time to Dial in for Key Catalysts Updates. July 15th'-'10:00AM EST
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Strong Preclinical Support for Ongoing Clinical Efforts Presented at AACR
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Company: GlycoMimetics, Inc.
Industry: Medical - Drugs
Rivipansel''s Post-Hoc Analysis in Sickle Cell Hints at a Path to Approval
Provider: Roth Capital Partners, Inc.
Analyst: JALLAH Z